Search Results - matthew+rettig

2 Results

Sort By:

Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)

Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...

Published: 9/23/2024 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2017-094: Inhibitors of the N-Terminal Domain of the Androgen Receptor

SUMMARYUCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.BACKGROUNDProstate...

Published: 7/19/2023 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)